Under construction – not a live service
Sign in
Taking peoplePhase 3

EloraTZP versus tirzepatide for excess weight and type 2 diabetes

Tests EloraTZP against tirzepatide in obesity with type 2 diabetes.

Key facts

Who runs it
Eli Lilly and Company
Where
Changchun, Jinan, Luoyang Shi, Nanjing, Ningbo, Shijiazhuang, and Tianjin, ChinaSee the 7 sitesAlso in 9 other countries, 68 sites
Registry title
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Status
Recruiting
Phase
Phase 3
People taking part
1,000 people, planned
Started
16 Oct 2026
Expected to end
Nov 2029
Type of study
Interventional, 2 groups
Treatments tested
  • eloralintide and tirzepatide
  • Tirzepatide
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who have obesity or overweight and have tried to lose weight by diet without success.

Age
18 years or older
Sex
All sexes can join
Disease stage
Type 2 diabetes with a BMI of ≥27 kg/m2 at screening
Earlier treatment
Must have tried at least 1 diet effort to lose weight that did not work. Must not have taken weight-loss medicines, amylin, GLP-1 or GIP drugs, DPP-4 inhibitors or insulin in the 90 days before screening. Must not have had weight-loss surgery, endoscopic procedures or device-based therapy (some exceptions are listed in the record).

Main reasons for not taking part

  • Type 1 diabetes
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure in the 90 days before screening
  • Class IV congestive heart failure (New York Heart Association)
  • Prior or planned surgery for obesity
  • Weight-loss medicines or alternative remedies in the 90 days before screening

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have type 2 diabetes
  • Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening
  • Have a BMI of ≥27 kg/m2 at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have taken any of the following within 90 days prior to screening; medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies; dipeptidyl peptidase 4 (DPP-4) inhibitors, and; insulin
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where in China

Also in 9 other countries, 68 sites

  • The Second Hospital of Jilin UniversityChangchun, ChinaContact: Hanqing Cai (principal investigator)Not yet recruiting
  • Jinan Central HospitalJinan, ChinaContact: Nianrong Mi (principal investigator)Not yet recruiting
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaContact: Hongwei Jiang (principal investigator)Not yet recruiting
  • The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Yibing Lu (principal investigator)Not yet recruiting
  • Ningbo First HospitalNingbo, ChinaContact: Li Li (principal investigator)Not yet recruiting
  • The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Huijuan Ma (principal investigator)Not yet recruiting
  • Tianjin Medical University Zhu Xianyi Memorial HospitalTianjin, ChinaContact: Liming Chen (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.

Read full original descriptionShow less

Participation in the study will last about 2 years.

The 2 groups in the trial

  • EloraTZPTreatment being tested

    Participants will receive EloraTZP subcutaneously (SC)

    Treatment: eloralintide and tirzepatide

  • TirzepatideTreatment being tested

    Participants will receive tirzepatide SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Plain-language title
EloraTZP versus tirzepatide for excess weight and type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
4 November 2026